Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Nektar and Takeda Explore Immunotherapy Combinations for Multiple Cancers. Sangamo Is Financing Through Public Offering

April 26, 2018 0

NEKTAR Nektar Therapeutics (NKTR) and Takeda Pharmaceutical (TKPYY) are collaborating to evaluate Nektar’s investigational medicine, NKTR-214, with Takeda’s investigational medicine, TAK-659, as a potential …

Alnylam’s RNAi Product Patisiran Has More Positive News

April 25, 2018 0

The Market The Stock Market is Still under pressure, which is frightening common investors, pressuring them …

The Biotech Revolution is Alive and Speeding

April 24, 2018 0

The Week in Review #21 Part 1 THE MARKET - Like symphonic orchestras that bring to the listeners’ …

Real Breakthroughs

April 17, 2018 0

Prohost Letter #420 REAL BREAKTHROUGHS - One Has Already Been Used and the Other Has Extraordinary …

Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial

April 12, 2018 0

Bellicum Pharmaceuticals (BLCM): The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on studies of BPX-501 in …

Illumina’s Contribution to Practicing Precision Medicine

April 11, 2018 0

When we reiterated that Illumina (ILMN) is the engine of the biotechnology evolution we meant it. We have …

Novartis to acquire AveXis. Would the Approval of AVXS-101, If Any, Impact the Sales of Ionis’ Spinraza?

April 10, 2018 0

NOVARTIS TO ACQUIRE AVEXIS A few months ago, Novartis (NVS) CEO agreed to cash out of the company’s …

Let’s Go Shopping

April 6, 2018 0

In today’s news, Incyte’s (INCY) immuno-oncology IDO1 inhibitor product Epacadostat in combination with Merck’s immuno-oncology product Keytruda® did not …

Yes, the Biotech Evolution is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis

April 5, 2018 0

THE BIOTECH EVOLUTION: AN UNPARALLELED SPEED The Tremendous Regret Investors Will Feel If They Sell the Best of the Best Biotechnology Firms …

Why Investors Caused a Selloff of Alnylam’s Stock

April 2, 2018 0

Alnylam (ALN) is probably experiencing a stock selloff following the announcement of successful results from Pfizer’s (PFE) drug tafamidis. …

News from PTC Therapeutics, Celgene and Heron Therapeutics

March 29, 2018 0

IN THE NEWS PTC THERAPEUTICS PTC Therapeutics (PTCT) stock, which dipped yesterday, probably on news announcing a …

An Erroneous Interpretation of an Outstanding Achievement in CRISPR Gene Editing

March 28, 2018 0

A False Reason for Unwarranted Selling of CRISPR/Cas9 Gene Editing Shares CRISPRs are bacterial immune systems …

Bull or Bear

March 26, 2018 0

The Week in Review #20 THE MARKET - My friend asked: “Are you scared?” “Of what?” …

Exelixis’ and Array’s Enchanting News

March 23, 2018 0

Exelixis: Delightful Overseas Cabozantinib News Ipsen (EPA:IPN) announced that the Committee for Medicinal Products for Human Use …

Regeneron Discovers the Therapeutic Target for Non-Viral Chronic Liver Diseases. Alnylam is Assigned to Discover and Create the Targeted RNAi Therapeutic

March 22, 2018 0

Regeneron (REGN) and Alnylam (ALNY) announced a collaborative agreement aimed at identifying RNAi therapeutics for the chronic liver disease …

Roche Checkpoint Inhibitor Conquers Squamous Non-Small-Cell Lung Cancer. See Also: Some Insight on Immunotherapy and More

March 21, 2018 0

In spite of their successes, Immuno-oncology products, which we still like to call immunotherapy for several …

Arena Pharmaceuticals: Positive Results on Ulcerative Colitis

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Nektar and Takeda Explore Immunotherapy Combinations for Multiple Cancers. Sangamo Is Financing Through Public Offering

Alnylam’s RNAi Product Patisiran Has More Positive News

The Biotech Revolution is Alive and Speeding

Real Breakthroughs

Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial

Illumina’s Contribution to Practicing Precision Medicine

Novartis to acquire AveXis. Would the Approval of AVXS-101, If Any, Impact the Sales of Ionis’ Spinraza?

Let’s Go Shopping

Yes, the Biotech Evolution is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis

Why Investors Caused a Selloff of Alnylam’s Stock

News from PTC Therapeutics, Celgene and Heron Therapeutics

An Erroneous Interpretation of an Outstanding Achievement in CRISPR Gene Editing

Bull or Bear

Exelixis’ and Array’s Enchanting News

Regeneron Discovers the Therapeutic Target for Non-Viral Chronic Liver Diseases. Alnylam is Assigned to Discover and Create the Targeted RNAi Therapeutic

Roche Checkpoint Inhibitor Conquers Squamous Non-Small-Cell Lung Cancer. See Also: Some Insight on Immunotherapy and More

Arena Pharmaceuticals: Positive Results on Ulcerative Colitis

Heron Therapeutics’ Product HTX-011: Helping in the War Against Opioids. Why Regeneron Could Fiercely Rebound

Exelixis: Further Stretching Its Cabozantinib’s Market

The Prohost Portfolio: Updating the Stock Targets